Search Results - Evangeline Pierce

The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata by Natasha Mesinkovska, Brittany Craiglow, Susan G. Ball, Paula Morrow, Sarah G. Smith, Evangeline Pierce, Jerry Shapiro

Connect to this object online.

Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale by Alissa Rams, Jessica Baldasaro, Laurine Bunod, Laure Delbecque, Sara Strzok, Juliette Meunier, Hany ElMaraghy, Luna Sun, Evangeline Pierce

Connect to this object online.

Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry by Jonathan I. Silverberg, Evangeline Pierce, Meghan Feely, Amber Reck Atwater, Amy Schrader, Eric A. Jones, Swapna S. Dave, Eric L. Simpson

Connect to this object online.

Impact of atopic dermatitis lesion locations and extent on patient burden: A real‐world study by Eric Simpson, Peter Lio, Evangeline Pierce, Angel Cronin, Robert R. McLean, Thomas Eckmann, Amber Reck Atwater, Zach Dawson, Jonathan I. Silverberg

Connect to this object online.

Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomize... by Bianca Maria Piraccini, Manabu Ohyama, Brittany Craiglow, Anthony Bewley, Yuxin Ding, Yun-Fei Chen, Yves Dutronc, Evangeline Pierce, Frederick Durand, Arash Mostaghimi

Connect to this object online.

Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two interna... by Bianca M. Piraccini, Manabu Ohyama, Brittany Craiglow, Anthony Bewley, Yuxin Ding, Yun‐Fei Chen, Yves Dutronc, Evangeline Pierce, Frederick Durand, Arash Mostaghimi

Connect to this object online.

Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial by Natasha Atanaskova Mesinkovska, Brett A. King, Sergio Vañó‐Galván, Yutaka Shimomura, Jakub Jedynak, Jill McCollam, Evangeline Pierce, Amy K. Ellinwood, Rodney Sinclair

Connect to this object online.

Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib by Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, Alexander Egeberg, Yves Dutronc, Frederick Durand, Evangeline Pierce, Guanglei Yu, Yun-Fei Chen, Arash Mostaghimi

Connect to this object online.

Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regro... by Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, Alexander Egeberg, Yves Dutronc, Frederick Durand, Evangeline Pierce, Guanglei Yu, Yun-Fei Chen, Arash Mostaghimi

Connect to this object online.

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a ra... by Jacob P. Thyssen, Thomas Werfel, Sebastien Barbarot, Hamish J.A Hunter, Evangeline Pierce, Luna Sun, Lisa Cirri, Andrew S. Buchanan, Na Lu, Andreas Wollenberg

Connect to this object online.

Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials by Jennifer Soung, Sonja Ständer, Jan Gutermuth, Ignasi Pau-Charles, Zach Dawson, Fan Emily Yang, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Linda Stein-Gold

Connect to this object online.

Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks by Gil Yosipovitch, Peter Lio, Franz J. Legat, Raj Chovatiya, Mette Deleuran, Evangeline Pierce, Marta Casillas, Yuxin Ding, Fan E. Yang, Laia Bardolet, Sonja Ständer

Connect to this object online.

The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis by Jennifer Soung, Vivian Laquer, Joseph F. Merola, Angela Moore, Hany Elmaraghy, Chaoran Hu, Maria Lucia Buziqui Piruzeli, Evangeline Pierce, Esther Garcia Gil, Abel D. Jarell

Connect to this object online.

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data fr... by Jonathan I. Silverberg, Vivian Y. Shi, Andrew Alexis, Evangeline Pierce, Angel Cronin, Robert R. McLean, Carla Roberts-Toler, Maria J Rueda, Amber R. Atwater, Eric Simpson

Connect to this object online.

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials by Adelaide A. Hebert, Carsten Flohr, H. Chih-ho Hong, Alan D. Irvine, Evangeline Pierce, Hany Elmaraghy, Sreekumar Pillai, Zach Dawson, Sherry Chen, Clara Armengol, Elaine Siegfried, Stephan Weidinger

Connect to this object online.

Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis by Peter A. Lio, April Armstrong, Jan Gutermuth, Audrey Nosbaum, Howard Sofen, Esther Garcia Gil, Marta Casillas, Sherry Chen, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Zach Dawson, Tiago Torres

Connect to this object online.

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment by Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline Pierce, Helena Agell, Sonja Ständer

Connect to this object online.

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment by Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline Pierce, Helena Agell, Sonja Ständer

Connect to this object online.

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study by Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield, Alan D. Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R. Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer, Stephan Weidinger

Connect to this object online.